Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

including diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma, after two or more lines of systemic therapy who are not ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

However, they raised questions about where the combination of lenalidomide, rituximab and brentuximab vedotin regimen fits into the treatment landscape for relapsed or refractory DLBCL given the ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

“Building on Columvi’s established benefits, [this] data demonstrate[s] the potential of this combination regimen to improve ... into the first-line DLBCL setting. To that end, Roche is ...

These investigators used SEER data to compare the outcomes of transformed indolent non-Hodgkin lymphomas with de novo DLBCL at a population level, a situation for which little data exist.

in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma ...

PFE Pfizer Inc U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma ...